These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24765618)

  • 1. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.
    Bison SM; Konijnenberg MW; Melis M; Pool SE; Bernsen MR; Teunissen JJ; Kwekkeboom DJ; de Jong M
    Clin Transl Imaging; 2014; 2(1):55-66. PubMed ID: 24765618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
    Giovacchini G; Nicolas G; Forrer F
    Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.
    Fani M; Mansi R; Nicolas GP; Wild D
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.
    Gabriel M; Andergassen U; Putzer D; Kroiss A; Waitz D; Von Guggenberg E; Kendler D; Virgolini IJ
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):92-9. PubMed ID: 20168291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors.
    Kim K; Kim SJ
    Nucl Med Mol Imaging; 2018 Jun; 52(3):208-215. PubMed ID: 29942399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.
    Feijtel D; de Jong M; Nonnekens J
    Curr Top Med Chem; 2020; 20(32):2959-2969. PubMed ID: 32101125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
    Shi M; Jakobsson V; Greifenstein L; Khong PL; Chen X; Baum RP; Zhang J
    Front Med (Lausanne); 2022; 9():1034315. PubMed ID: 36569154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
    van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
    Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
    Adant S; Shah GM; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin Receptor 2-Targeting Compounds.
    Smit Duijzentkunst DA; Kwekkeboom DJ; Bodei L
    J Nucl Med; 2017 Sep; 58(Suppl 2):54S-60S. PubMed ID: 28864613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.
    Bodei L; Ćwikla JB; Kidd M; Modlin IM
    J Thorac Dis; 2017 Nov; 9(Suppl 15):S1511-S1523. PubMed ID: 29201454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-receptor radionuclide therapy for endocrine tumors.
    van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
    Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements.
    Merola E; Grana CM
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapies with PRRT.
    Yordanova A; Ahmadzadehfar H
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.